January 29-31 2019
Boston, MA

 

 

Speaker Faculty

Expand/Collapse

Maulik Patel
Senior Clinical Scientist
AbbVie

I am a senior clinical PK/PD scientist-II at AbbVie Inc., in Redwood City, CA. I serve as a clinical pharmacology lead for multiple early phase clinical immunotherapy programs. I lead clinical and translational quantitative pharmacokinetic/pharmacodynamics (PK/PD) modeling efforts integrating immune biomarkers to provide dose/regimen rationale for selecting the recommended Phase 2 dose (RP2D) for immunotherapies. I am currently serving as a faculty member for SITC Cancer Immune Responsiveness Task Force and a member of PACT novel biomarker working group.  

Day Two

Thursday January 31st, 2019

15.00 | Generation of DDR pathways-centered ctDNA panel to inform patient stratification for immunotherapy

Graeme Smith
Chief Scientific Officer
Artios Pharma Ltd.

Graeme is currently CSO at Artios with responsibility for their drug discovery and target validation projects in the area of DDR.  Prior to Artios, Graeme held the position of Senior Director of Bioscience at AstraZeneca within the Oncology IMED division. In this role, Graeme led a group of bioscientists in target validation and the discovery and development of novel anti-cancer agents. Prior to joining AstraZeneca, he was Research Director at KuDOS Pharmaceuticals where he played a key role in the discovery and early development of Lynparza™ (olaparib), the first targeted DDR inhibitor to reach the market.

Day One

Wednesday January 30th, 2019

11.30 | Panel Discussion: Assessing Lessons Learnt from Clinical Success and Challenges of PARP Inhibitors

J. Carl Barrett
Vice President of Translational Science in Oncology
AstraZeneca

Dr. J. Carl Barrett is Vice President of Translational Science in Oncology at AstraZeneca. He is responsible for development and execution of  biomarker strategies and translational sciences efforts to support compound development from research through early and full development in oncology. From 2005-2011, he was Global Head of Oncology Biomarkers and Imaging at Novartis. Dr. Barrett was the founding Director of the NCI Center for Cancer Research (CCR), the NCI intramural center for translation medicine. He was also Scientific Director at the National Institute of Environmental Health Sciences where he focused on integrating new approaches to toxicogenomics, molecular toxicology, and the Environmental Genome Project. Dr. Barrett’s  research  focused on the discovery of the critical genetic and epigenetic changes in the cancer cell, in particular the discovery of genes involved in breast cancer (BRCA1). Trained as a chemist at the College of William and Mary, he received his Ph.D. degree in Biophysical Chemistry from Johns Hopkins University. He has published over 600 research articles. He is a member of the Johns Hopkins University Society of Scholars, the Ramazini Foundation, an honorary member of the Japanese Cancer Association, and a recipient of multiple NIH awards and Keynote lectures.

Day One

Wednesday January 30th, 2019

11.30 | Panel Discussion: Assessing Lessons Learnt from Clinical Success and Challenges of PARP Inhibitors

Shuichan Xu
Senior Principal Scientist & Group Leader
Celgene

Day One

Wednesday January 30th, 2019

10.00 | Preclinical Characterization of a Clinical Development Candidate CC-115, a Dual Inhibitor of mTOR Kinase and DNA-PK

Ranjit Bindra
Co-Founder
Cybrexa Therapeutics

Dr. Ranjit Bindra is a physician-scientist at the Yale School of Medicine. Clinically, he treats adult and pediatric primary CNS tumors. In the laboratory, his group recently led a team of four major laboratories at Yale. As a biotech entrepreneur, Dr. Bindra has started several life sciences ventures over the last 10 years. Most recently, he co-founded Cybrexa Therapeutics, a Series B round-funded company focused on developing an entirely new class of small molecule DNA repair inhibitors, which directly target the tumor microenvironment. which reported the stunning discovery that IDH1/2-mutant tumors harbor a profound DNA repair defect that renders them exquisitely sensitive to PARP inhibitors. This work was published in Science Translational Medicine, and it has received international attention with major clinical implications. Building on this discovery, a more recent study in his laboratory was published in Nature Genetics, which highlights the expanding significance of this work: specific tumor-associated mutations induce the aberrant production of citric acid cycle-related metabolites, which drives genetic instability and BRCAness. Dr. Bindra is now translating this work directly into patients, in four phase I/II clinical trials, including an innovative, biomarker-driven trial specifically targeting the Adolescent/Young Adult (AYA) cancer patient population. In addition, he is lead co-PI of a 35-site, NCI-sponsored Phase II trial testing the PARP inhibitor, olaparib, in adult IDH1/2-mutant solid tumors (NCT03212274). As a biotech entrepreneur, Dr. Bindra has started several life sciences ventures over the last 10 years. Most recently, he co-founded Cybrexa Therapeutics, a Series B round-funded company focused on developing an entirely new class of small molecule DNA repair inhibitors, which directly target the tumor microenvironment. This approach leverages a novel tumor-localizing peptide technology developed by an internationally recognized research laboratory at Yale. Cybrexa is led by an experienced business team that has built numerous successful biotech ventures and raised hundreds of millions of dollars in venture capital. Dr. Bindra received his undergraduate degree in Molecular Biophysics and Biochemistry from Yale University in 1998, and both his MD and PhD from the Yale School of Medicine in 2007. He completed his medical internship, radiation oncology residency, and post-doctoral research studies at the Memorial Sloan-Kettering Cancer Center in 2012.

Pre-Conference Workshop B

Tuesday January 29, 2019

1.00pm | Optimizing Screening Tools to Uncover Synthetic Lethal Drug Interactions in DNA Repair Pathways

Day One

Wednesday January 30th, 2019

14.30 | PARP Inhibitors in the New Era, New Targets & New Targeting Techniques

Geoffrey Shapiro
Director, Early Drug Development Center
Dana Farber Cancer Institute

Dr Shapiro conducts both basic and translational research on cyclin-dependent kinase inhibitors. A major goal is to define the role of one of these inhibitors, p16ink4a in the cellular response to DNA damage. In addition, Dr Shapiro is directing both preclinical and clinical studies of several potent pharmacologic cyclin-dependent kinase inhibitors. Several phase I trials are underway investigating these agents in patients with advanced solid tumors. The work involves the assessment of these drugs alone, as well as in combination with standard chemotherapy agents and signal transduction inhibitors. Dr Shapiro completed a fellowship in medical oncology at Dana-Farber Cancer Institute, during which he investigated the role of cell-cycle-related proteins in lung cancer. He joined the Dana-Farber faculty in 1994. He received his PhD in 1987 and his MD in 1988 from Cornell University, followed by postgraduate training in internal medicine at Beth Israel Hospital, Boston, where he served as chief medical resident.

Day One

Wednesday January 30th, 2019

11.30 | Panel Discussion: Assessing Lessons Learnt from Clinical Success and Challenges of PARP Inhibitors

Day Two

Thursday January 31st, 2019

12.30 | Panel Discussion: Developing Optimal Combination Strategies in the Clinic

Sharon McGonigle
Senior Principal Scientist
Eisai

Sharon McGonigle is a Senior Principal Scientist at Eisai Inc., where she leads pre-clinical biology in discovery and early development programs for oncology.  Her >10 years Eisai experience spans target validation and mechanism of action activities in early discovery, to IND-enabling studies, guidance and support of preclinical programs through clinical introduction, in addition to biomarker and translational studies.  Prior to Eisai she worked at 2 start-up biotechnology companies in the Boston area in similar roles.  She held post-doctoral positions at MUSC (Charleston, SC) and Cornell University (Ithaca, NY) and she completed her PhD in Dublin, Ireland.

Day Two

Thursday January 31st, 2019

14.30 | 2X 121 (E7449), a Dual PARP1/2 and Tankyrase1/2 Inhibitor & Its Novel Drug Response Predictor Biomarker

Alan D’Andrea
Professor of Radiation Oncology
Harvard Medical School

Dr. D’Andrea is the Fuller-American Cancer Society Professor of Radiation Oncology at Harvard Medical School and the Director of the Center for DNA Damage and Repair at the Dana-Farber Cancer Institute. A recipient of numerous academic awards, Dr. D’Andrea is a Distinguished Clinical Investigator of the Doris Duke Charitable Trust, a Fellow of the American Association for the Advancement of Science, and a member of the National Academy of Medicine. He is also the recipient of the 2012 G.H.A. Clowes Memorial Award from the American Association for Cancer Research. Dr. D’Andrea participates in a wide range of clinical trials, largely focused on ovarian, breast, prostate, pancreatic, and bladder cancers. In 2017, he became the Director of the Susan Smith Center for Women’s Cancer at the Dana-Farber Cancer Institute.  

Day Two

Thursday January 31st, 2019

10.00 | Leveraging DNA Repair Inhibitor Combinations to Overcome PARP Inhibitor Resistance

Lee Zou
Professor Pathology
Harvard Medical School

Dr. Lee Zou is a Professor of Pathology at Harvard Medical School, Associate Scientific Director of  the Massachusetts General Hospital Cancer Center, and the James & Patricia Poitras Endowed Chair in Cancer Research at Massachusetts General Hospital. He obtained his Ph.D. training from Dr. Bruce Stillman at the Cold Spring Harbor Laboratory, and his postdoctoral training from Dr. Steve Elledge at Baylor College of Medicine and Harvard Medical School. Dr. Zou’s research is focused on understanding how ATM and ATR checkpoint pathways sense and signal DNA damage in human cells. Work by Dr. Zou has elucidated the key DNA damage sensors of the ATR checkpoint, and provided new strategies for targeted cancer therapy.  

Day One

Wednesday January 30th, 2019

12.30 | Targeting Spliceosome Mutations in Cancer Cells to Advance Therapeutics ATR Inhibitors

Michael Dillon
Chief Scientific Officer
Ideaya

Mike brings over 20 years of experience in drug discovery. He joined IDEAYA Biosciences as Senior Vice President, Head of Drug Discovery in April 2016, and has served as Senior Vice President and Chief Scientific Officer, Head of Research since February 2018. From 2008 to 2016, Mike was with the Novartis Institutes for Biomedical Research (NIBR) where he served in various leadership roles, including Global Discovery Chemistry Head, Oncology and New Therapeutic Modalities; Head of Chemical Sciences, Emeryville, and Executive Director Oncology Chemistry. Under his leadership at NIBR, several small molecules were advanced towards the clinic, including, PI3K inhibitor BKM120, CSF1R inhibitor BLZ945, V600E mutant B-RAF kinase inhibitor Encorafenib, PIM kinase inhibitor PIM447, ERK inhibitor LTT462, and RAF kinase inhibitor LXH254. From 1993 to 2008, Mike worked at Roche and Syntex (acquired by Roche), where he served in roles of increasing responsibility, including Director, Medicinal Chemistry. At Roche, he led multiple small molecule programs that advanced to the clinic, including first-in-class P2X3 antagonist Gefapixant, now being developed by Merck. Mike is an author on over 60 publications and patents. Mike obtained his B.Sc. (Hons) from the University of Leicester, and his Ph.D. in Chemistry from the University of Bristol. He completed his postdoctoral fellowship at Oregon State University to continue his research in Chemistry with Professor James D. White.

Day Two

Thursday January 31st, 2019

12.30 | Panel Discussion: Developing Optimal Combination Strategies in the Clinic

Sui Xiong Cai
Chief Technology Officer
Impact Therapeutics

Sui Xiong Cai, Ph. D. is SVP and CTO of IMPACT Therapeutics Inc. Dr. Cai previously served as Senior Director of chemistry in several biotechs, including EpiCept, Maxim Pharmaceuticals, and Cytovia and has over 20 years of experience in oncology and CNS drug discovery and development. He has extensive experience with technological innovation, capital operation, fund raising, outsourcing, corporate collaborations, and overall management of biotech companies. He is a co-inventor of 90 issued US patents. Dr. Cai earned his PhD in organic chemistry from the University of Oregon, and his BS in chemistry from the University of Science and Technology of China.

Day One

Wednesday January 30th, 2019

09.30 | Discovery & Clinical Development of IMP4297, A Potential Best-in-Class PARP Inhibitor

Eytan Ruppin
Chief of Cancer Data Science Lab
National Cancer Institute National Institute of Health

Joo Sang lee
Research Fellow Cancer Data Science Lab National Cancer Institute
National Institute of Health

Joo Sang Lee is a senior member of the newly established Cancer Data Science Lab at NCI/NIH. In this position, Joo leads the research on harnessing genetic interactions, with emphasis on synthetic lethality, to advance precision cancer medicine. His research studies the applications of synthetic lethality to identify biomarkers and stratify patients for therapy, and for identifying novel combinations for both targeted and immunotherapies.

Pre-Conference Workshop A

Tuesday January 29, 2019

09.00am | Harnessing Genetic Interactions to Advance Whole Genome Precision Cancer Medicine

Françoise Bono
Chief Scientific Officer
Onxeo

Senior research and development director with 25 years of experience in the pharmaceutical industry, oncology, vascular biology and immune-inflammation. Strong experience in science, people management and project leadership and evaluation, and recognized expertise in translational and development strategy in oncology. Previous positions: Executive vice president (EVP) Oncology EVOTEC - Senior vice president (SVP) Early to candidate Department SANOFI. Membership to Committees and boards - Coordinator of major collaborations in discovery and translational medicine projects - Member of Joint Steering Committees for international research collaborations - Active and frequent participations in the evaluation of external opportunities (compounds – technologies). Author of 75 publications and co-inventor of 25 patents.

Day One

Wednesday January 30th, 2019

14.00 | AsiDNA, A First-in-Class Decoy Oligonucleotide Targeting DNA Repair to Kill Tumor Cells

Ross Stewart
Director, Early Development & Translational Oncology
Pfizer

Ross Stewart is part of the Translational Oncology group within Pfizer global product development, where he leads translational strategy and execution across a range of clinical studies exploring the activity of avelumab (anti-PD-L1) both as monotherapy and in combination with the PARP inhibitor talazoparib. Previously he spent 10 years at MedImmune, where he played a pivotal role in establishing the preclinical platforms supporting immuno-oncology discovery, and lead a number of preclinical programs including durvalumab (anti-PD-L1) before joining the translational medicine group, where he lead translational activities for a number of durvaluamb and tremelimumab (anti-CTLA-4) studies as well as early immuno-oncology programs targeting GITR and CD73.  

Day Two

Thursday January 31st, 2019

10.30 | PARP and PD-1/L1: The Perfect Partners?

Michael Zinda
Executive Vice President Head of R&D
Repare Therapeutics

Day Two

Thursday January 31st, 2019

12.30 | Panel Discussion: Developing Optimal Combination Strategies in the Clinic

Christian Hassig
Chief Scientific Officer
Sierra Oncology

Jing Yu Wang
Senior Director, Translational Strategy and Research
Tesaro

Jing Wang, Ph.D. is a Sr. Director of Translational Research and Strategy at TESARO Inc., leading the translational development of PARP inhibitor Zejula (niraparib) since she joined TESARO in 2016 as a Director of Translation Research and Strategy. Prior to that, Dr. Wang served in six positions at Curis Inc. from 2006 to 2016, most recently as Director, Head of Preclinical and Translational Biomarker Research. Dr. Wang earned a B.S. from Beijing University in Physiology and Biophysics, and received her Ph.D. in Medical Science from Harvard Medical School.  

Day Two

Thursday January 31st, 2019

11.30 | Preclinical Anti-tumor Activity of Niraparib and its Combination with Anti-PD-1 Therapy

Jianfang Ning
Assistant Professor, Neurosurgery
University of Minnesota Medical School

Jianfang Ning (PhD), I worked at Neurosurgery Department of Mass General Hospital, Harvard Medical School from a postdoc to Instructor during 2012-2018 and currently works at Medical School at University of Minnesota as an Assistant Professor. My research has been focusing on developing novel therapeutic approaches for cancers, especially for brain tumors, applying cancer stem cell models and using oncolytic virus (OV) and molecular targeted therapeutics through targeting DNA damage responses (DDR) in cancer cells.

Day Two

Thursday January 31st, 2019

12.00 | PARP Inhibitor Combinations Targeting Glioblastoma Stem-like Cells